Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Neutropenia in GSD Ib and G6PC3 Deficiency
NCT04138251Phase 2Unknown
- Start
- Jun 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in glycogen storage disease type Ib, Severe congenital neutropenia due to glucose-6-phosphatase catalytic subunit 3 deficiency. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
glycogen storage disease type IbSevere congenital neutropenia due to glucose-6-phosphatase catalytic subunit 3 deficiency
Beyond the preview
Go deeper on NCT04138251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04138251.